biOasis Receives Compelling Data From Texas Tech University On Its Herceptin(R) BT2111 Program - Yahoo! Finance
|
biOasis Technologies Inc. (TSX VENTURE:BTI) announced today that research underway at Texas Tech University Health Sciences Center (TTUHSC) has yielded some compelling data on preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of Transcend and Herceptin®) in animal models of breast cancer metastasis to the brain. Read the full story >> |
Related Stories
How Does Your Garden Grow?
As spring approaches, some people’s thoughts turn to gardening. Whether it’s a flower garden they desire or a vegetable garden want to have, they begin planning what they’ll plant and what they need to do to ensure a successful garden.
Adopt a Growth Mindset for a Better Life
A “growth mindset” accepts that our intelligence and talents can develop over time, and a person with that mindset understands that intelligence and talents can improve through effort and learning.
Drug Use, Family History Can Lead to Heart Disease in Younger Adults
Abstaining from drug abuse and an early diagnosis of familial hypercholesterolemia (high cholesterol) can help prevent heart disease.
Recent Stories
TTUHSC’s La-Beck to Use NIH Grant to Study Cancer Drug Delivery Via Nanoparticles
Ninh (Irene) La-Beck, Pharm.D., with the TTUHSC Jerry H. Hodge School of Pharmacy, received a five-year, $2.49 million grant to investigate how nanoparticles interact with the immune system and cancer.
TTUHSC’s Wilkerson to Investigate Links Between Pain and Basal Sex Hormone Levels
To help investigate the influence basal sex hormone alterations may have on chronic post-op pain, the NIH recently awarded a grant to Jenny Wilkerson, Ph.D., from the Jerry H. Hodge School of Pharmacy.
Tackling Heart Health for Athletes
Scott Shurmur, M.D., a cardiologist at the Texas Tech Physicians Center for Cardiovascular Health, shared his expertise and his experience as a former collegiate athlete.